11-4-9　ⓔ文献

  1. Lokuhetty D, White VA, et al: WHO classification of tumors. Digestive system tumors, 5th ed, IARC Press, 2019.

  2. Isaacson P, Wright DH: Malignant lymphoma of mucosa–associated lymphoid tissue. A distinctive type of B–cell lymphoma. Cancer, 1983; 52: 1410–1416.

  3. Rohatiner A, d’Amore F, et al: Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol, 1994; 5: 397–400.

  4. 日本ヘリコバクター学会ガイドライン作成委員会：H. pylori感染の診断と治療のガイドライン2016年改訂版，先端医学社，2016; 16–17.

  5. Nakamura S, Sugiyama T, et al: Long–term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow–up study of 420 patients in Japan.Gut, 2012; 61: 507–513.

  6. 石倉　聡，石黒信吾，他：付 胃悪性リンパ腫診療の手引き．胃癌治療ガイドライン 第3版 医師用 (日本胃癌学会編)，金原出版，2010; 47–61.

  7. 赤司浩一：H. pylori陽性限局期胃MALTリンパ腫の初期治療方針は何が勧められるか．造血器腫瘍診療ガイドライン 2018年版 (日本血液学会編)，金原出版，2018; 197–254.

  8. NCCN Clinical Practice Guidelines in Oncology: B–cell lymphomas, Version 2.2015. https://oncolife.com.ua/doc/nccn/B-Cell_Lymphomas.pdf

  9. Schechter NR, Portlock CS, et al: Treatment of mucosa–associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol, 1998; 16: 1916–1921.

  10. Okada H, Takemoto M, et al: A prospective analysis of efficacy and long–term outcome of radiation therapy for gastric mucosa–associated lymphoid tissue lymphoma. Digestion, 2012; 86: 179–186.

  11. Ishikura S, Tobinai K, et al: Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I–II, diffuse large B–cell lymphoma of the stomach. Cancer Sci, 2005; 96: 349–352.

  12. Takata K, Okada H, et al: Primary gastrointestinal follicular lymphoma involving the duodenal second portion is a distinct entity: a multicenter, retrospective analysis in Japan. Cancer Sci, 2011; 102: 1532–1536.

  13. Ambinder AJ, Shenoy PJ, et al: Using primary site as a predictor of survival in mantle cell lymphoma. Cancer, 2013; 119: 1570–1577.

  14. Romaguera JE, Fayad L, et al: High rate of durable remissions after treatment of newly diagnosed aggressive mantle–cell lymphoma with rituximab plus hyper–CVAD alternating with rituximab plus high–dose methotrexate and cytarabine. J Clin Oncol, 2005; 23: 7013–7023.